ASCVD, Atherosclerotic Cardiovascular Disease; HF, Heart Failure; eGFR, Estimated Glomerular Filtration Rate; NAFLD, Non-Alcoholic Fatty Liver Disease; MAFLD, Metabolic (Dysfunction)-Associated Fatty Liver Disease; SU, Sulfonylurea; TZDs, Thiazolidinediones; DPP-4, Dipeptidyl Peptidase-4; SGLT2, Sodium–Glucose Cotransporter-2; GLP-1, Glucagon-Like Peptide-1; SC, Subcutaneous;. This evidence concerns the gene SLC5A2 and metabolic dysfunction-associated steatotic liver disease.